Granules India gets USFDA EIR for Bonthapally facility

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-10-29 08:00 GMT | Update On 2025-10-29 08:00 GMT

Hyderabad: Granules India Limited, a pharmaceutical manufacturing company, has announced that it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its API Unit-I facility located at Bonthapally, Hyderabad.

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025.

There was one observation during that inspection, and the Company had submitted its response within the stipulated time.

"The successful completion of this US FDA inspection and the subsequent receipt of the EIR with a satisfactory VAI classification reflects our commitment to maintaining the highest quality standards in our manufacturing operations," said Dr. Krishna Prasad Chigurupati, Chairman & Managing Director.

Along with Paracetamol APIs, the Company has established Metformin and Guaifenesin API manufacturing plants in the same facility.

Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered in Hyderabad with best-in-class facilities. Amongst the few pharmaceutical companies in the world to be present across the manufacturing of the entire pharmaceutical value chain — from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFls), and Finished Dosages (FDs), Granules products are distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US and UK. The Company has 10 manufacturing facilities out of which 8 are located in India and 2 are in the USA and has regulatory approvals from the US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Granules India gets USFDA EIR for Bonthapally facility

Similar News

Thermo Fisher Scientific inaugurates expanded RnD Centre of Excellence in Bengaluru

Pulse Pharma Gets CDSCO Panel Nod to Manufacture, Market Aripiprazole Oral Solution

Maha: Rs 14-Crore Mephedrone Unit Busted Near Police Station, Cop Suspended for Negligence

MP FDA Moves Rs 320-Crore Proposal to CDSCO, FSSAI to Upgrade Drug, Food Testing Labs

Alembic Pharma wins USFDA nod for heart disease drug

Lupin inaugrates new corporate offices in New Jersey

Koselugo approved in EU for plexiform neurofibromas in adults with neurofibromatosis type 1: AstraZeneca